RNAi therapeutics have shown great success with multiple US Food and Drug Administration (FDA)-approved products involving N-acetyl galactosamine (GalNAc)-conjugated siRNAs to treat liver-targeted ...
Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first ...
Sirnaomics raised the money to advance a pipeline of drug candidates underpinned by its polypeptide nanoparticle (PNP) and GalNAc (N-Acetylgalactosamine) technology platforms (Fig. 1). PNP offers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback